ClinicalTrials.gg
CompletedNCT03875482Updated Mar 16, 2021Results posted

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of Risankizumab and Placebo solution for risankizumab in Psoriasis, sponsored by AbbVie. Completed at 43 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-16.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
157
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.

Enrollment
16th of 30
157 · median 162
Started
2019
with 2 others
Phase 3
17 of 30
none open now
Registered
16th of 30
by date
Lead sponsor
24 of 30
AbbVie

Among the 30 studies testing risankizumab in Psoriasis, this one is the 16th largest by enrollment, is one of 3 that started in 2019, is one of 17 in phase 3, and was the 16th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing risankizumab in Psoriasis, or all of them as a file.
02

Study summary

The primary objective of this study was to evaluate the safety and efficacy of risankizumab (150 mg/mL) administered by prefilled syringe (PFS) for the treatment of adult participants with moderate to severe plaque psoriasis.

Read the detailed description

This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of risankizumab 150 mg/mL formulation in PFS in adult participants with moderate to severe plaque psoriasis. The study included a 30-day screening period, a 28-week treatment period with study visits at Weeks 0, 4, 16 and 28, and a subsequent follow-up telephone call at approximately 20 weeks after the last dose of study drug. Study drug dosing consisted of 3 self-administered, subcutaneous (SC) doses on Weeks 0, 4, and 16. Dosing on Week 4 was self-administered at home.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Risankizumab
  • Psoriasis
  • Plaque Psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has diagnosis of chronic plaque psoriasis for at least 6 months before the baseline visit.
  • Participant meets following disease activity criteria:
  • Stable moderate to severe chronic plaque psoriasis, defined as greater than or equal to 10% body surface area (BSA) psoriasis involvement, static physician global assessment (sPGA) score of greater than or equal to 3, and Psoriasis Area Severity Index (PASI) greater than or equal to 12 at Screening and baseline visit.
  • Candidate for systemic therapy as assessed by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Participant has history of active skin disease other than psoriasis that could interfere with the assessment of psoriasis.
  • Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis.
  • Participant has previous exposure to risankizumab.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
157 participants (actual)

Study arms

  • Experimental
    Risankizumab

    Subcutaneous (SC), self-administered 150 mg doses of risankizumab at Weeks 0, 4, and 16

    Drug: Risankizumab

  • Placebo comparator
    Placebo

    Subcutaneous (SC), self-administered doses of placebo solution at Weeks 0, 4, and 16

    Drug: Placebo solution for risankizumab

Interventions

  • Risankizumab 150 mg (150 mg/mL) in prefilled syringes, self-administered subcutaneously

    Also known as: ABBV-066, BI 655066

  • DrugPlacebo solution for risankizumab

    Placebo solution in prefilled syringes, self-administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 at Week 16

    The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at Week 16) / PASI score at Baseline \* 100.

    Time frame: At Week 16

  2. Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear or Almost Clear at Week 16

    The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema, induration, and scaling of psoriatic lesions are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5.

    Time frame: At Week 16

Secondary outcomes

  1. Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 100 at Week 16

    The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at Week 16) / PASI score at Baseline \* 100.

    Time frame: At Week 16

  2. Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear at Week 16

    The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema, induration, and scaling of psoriatic lesions are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5.

    Time frame: At Week 16

Other outcomes

  1. Percent Change From Baseline in Psoriasis Area Severity Index (PASI) Score up to Week 16

    The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked.The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. Negative values indicate an improvement from baseline.

    Time frame: Baseline, Week 4, and Week 16

07

Results

Posted Mar 16, 2021

Participant flow

Participant flow — Overall Study
MilestoneRisankizumabPlacebo
Started10552
Completed9232
Not completed1320
Withdrew: Adverse event01
Withdrew: Withdrew consent56
Withdrew: Lost to follow-up82
Withdrew: Lack of efficacy011

Outcome measures

PrimaryPercentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 at Week 16

The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at Week 16) / PASI score at Baseline \* 100.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 at Week 16
percentage of participantsRisankizumabPlacebo
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 at Week 1662.9 (53.6 to 72.1)3.8 (0.0 to 9.1)
Statistical analysis
  • Risankizumab vs Placebo · Chi-squared · p = <0.001 · Mean difference: 59.0 · 95% CI 48.4 to 69.6
PrimaryPercentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear or Almost Clear at Week 16

The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema, induration, and scaling of psoriatic lesions are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear or Almost Clear at Week 16
percentage of participantsRisankizumabPlacebo
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear or Almost Clear at Week 1678.1 (70.2 to 86.0)9.6 (1.6 to 17.6)
Statistical analysis
  • Risankizumab vs Placebo · Chi-squared · p = <0.001 · Mean difference: 68.5 · 95% CI 57.2 to 79.7
SecondaryPercentage of Participants Achieving Psoriasis Area Severity Index (PASI) 100 at Week 16

The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at Week 16) / PASI score at Baseline \* 100.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 100 at Week 16
percentage of participantsRisankizumabPlacebo
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 100 at Week 1638.1 (28.8 to 47.4)1.9 (0.0 to 5.7)
Statistical analysis
  • Risankizumab vs Placebo · Chi-squared · p = <0.001 · Mean difference: 36.2 · 95% CI 26.2 to 46.2
SecondaryPercentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear at Week 16

The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema, induration, and scaling of psoriatic lesions are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear at Week 16
percentage of participantsRisankizumabPlacebo
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear at Week 1639.0 (29.7 to 48.4)1.9 (0.0 to 5.7)
Statistical analysis
  • Risankizumab vs Placebo · Chi-squared · p = <0.001 · Mean difference: 37.1 · 95% CI 27.1 to 47.2
Other pre-specifiedPercent Change From Baseline in Psoriasis Area Severity Index (PASI) Score up to Week 16

The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked.The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. Negative values indicate an improvement from baseline.

Time frame:
Baseline, Week 4, and Week 16
Reported as:
Least squares mean · percent change from Baseline
Percent Change From Baseline in Psoriasis Area Severity Index (PASI) Score up to Week 16
percent change from BaselineRisankizumabPlacebo
Week 4-50.62 (-56.255 to -44.987)-14.48 (-22.490 to -6.470)
Week 16-89.36 (-95.200 to -83.522)-29.39 (-38.152 to -20.630)
Statistical analysis
  • Risankizumab vs Placebo · Mixed-effect Model Repeat Measurements · p = <0.001 · Ls mean difference: -36.14 · 95% CI -45.936 to -26.346Risankizumab - placebo
  • Risankizumab vs Placebo · Mixed-effect Model Repeat Measurements · p = <0.001 · Ls mean difference: -59.97 · 95% CI -70.501 to -49.439Risankizumab - placebo

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the first dose of study drug until 20 weeks following discontinuation of study drug administration have elapsed, up to 48 weeks. In addition, serious adverse events were collected from the time the participant signed the study-specific informed consent.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Risankizumab0/105 (0%)1/105 (1%)0/105 (0%)
Placebo0/52 (0%)0/52 (0%)0/52 (0%)
Most frequent serious events
Most frequent serious events
EventRisankizumabPlacebo
PANCREATITIS ACUTEGastrointestinal disorders1/1050/52

Baseline characteristics

Intent-to-treat (ITT) population: all randomized participants

Age, Continuous
Age, Continuous(years)RisankizumabPlaceboTotal
Mean49.3 ± 15.1448.8 ± 15.4749.1 ± 15.20
Sex: Female, Male
Sex: Female, Male(Participants)RisankizumabPlaceboTotal
Female462470
Male592887
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RisankizumabPlaceboTotal
White8744131
Black or African American12416
Asian314
American Indian or Alaska Native101
Native Hawaiian or other Pacific Islander123
Multiple112
Prior Use of Systemic Biologic for Psoriasis
Prior Use of Systemic Biologic for Psoriasis(Participants)RisankizumabPlaceboTotal
0582987
≥1472370
Static Physician Global Assessment (sPGA) Score at Baseline
Static Physician Global Assessment (sPGA) Score at Baseline(Participants)RisankizumabPlaceboTotal
Score of 38646132
Score of 419625
Psoriasis Area and Severity Index (PASI) Score at Baseline
Psoriasis Area and Severity Index (PASI) Score at Baseline(units on a scale)RisankizumabPlaceboTotal
Mean21.529 ± 9.597521.060 ± 10.256321.373 ± 9.7901
Body Surface Area (BSA) Psoriasis Involvement at Baseline
Body Surface Area (BSA) Psoriasis Involvement at Baseline(Percentage of body surface area affected)RisankizumabPlaceboTotal
Mean28.343 ± 16.413928.160 ± 18.486828.282 ± 17.0689
Duration of Plaque Psoriasis
Duration of Plaque Psoriasis(years)RisankizumabPlaceboTotal
Mean20.91 ± 13.83715.82 ± 11.75319.22 ± 13.363
08

Study locations

43 sites
  • Total Skin and Beauty Derm Ctr /ID# 210366
    Birmingham, Alabama 35205, United States
  • Alliance Dermatology and MOHs /ID# 210645
    Phoenix, Arizona 85032, United States
  • Hull Dermatology, PA /ID# 210305
    Rogers, Arkansas 72758, United States
  • Anaheim Clinical Trials LLC /ID# 212559
    Anaheim, California 92801-2658, United States
  • Wallace Medical Group, Inc. /ID# 210403
    Beverly Hills, California 90211, United States
  • Dermatology Res. Assoc., CA /ID# 210402
    Los Angeles, California 90045, United States
  • Integrative Skin Science and Research /ID# 212551
    Sacramento, California 95815-4500, United States
  • Mosaic Dermatology /ID# 210780
    Santa Monica, California 90404, United States
  • Skin Care Research, LLC /ID# 210514
    Boca Raton, Florida 33486-2269, United States
  • ACCEL Research Sites /ID# 212709
    DeLand, Florida 32720, United States
  • Multi-Speciality Research Associates /ID# 211625
    Lake City, Florida 32055-8835, United States
  • GSI Clinical Research, LLC /ID# 210330
    Margate, Florida 33063, United States
  • Suncoast Clinical Research /ID# 210874
    New Port Richey, Florida 34652, United States
  • Ormond Medical Arts Pharmaceutical Research Center /ID# 212781
    Ormond Beach, Florida 32174-6302, United States
  • Progressive Medical Research /ID# 210877
    Port Orange, Florida 32127, United States
  • Precision Clinical Research /ID# 212921
    Sunrise, Florida 33351-7311, United States
  • Lenus Research & Medical Group /ID# 212584
    Sweetwater, Florida 33172, United States
  • Treasure Valley Dermatology /ID# 212707
    Boise, Idaho 83713-0997, United States
  • Sneeze, Wheeze, & Itch Associates, LLC /ID# 212562
    Normal, Illinois 61761, United States
  • The Indiana Clinical Trials Center /ID# 210205
    Plainfield, Indiana 46168, United States
  • Forefront Dermatology /ID# 210520
    Louisville, Kentucky 40202-2862, United States
  • DS Research /ID# 210272
    Louisville, Kentucky 40241-6162, United States
  • David Fivenson, MD, PLC /ID# 210193
    Ann Arbor, Michigan 48103, United States
  • Clarkston Skin Research /ID# 210197
    Clarkston, Michigan 48346, United States
  • Henry Ford Medical Center /ID# 211598
    Detroit, Michigan 48202-3046, United States
  • Cleaver Dermatology /ID# 210300
    Kirksville, Missouri 63501-5362, United States
  • Advanced Dermatology of the Midlands /ID# 212763
    Omaha, Nebraska 68144-1105, United States
  • Skin Specialists, PC /ID# 211490
    Omaha, Nebraska 68144, United States
  • Psoriasis Treatment Ctr NJ /ID# 210837
    East Windsor, New Jersey 08520, United States
  • Skin Laser and Surgery Specialists of NY and NJ /ID# 210208
    Hackensack, New Jersey 07601-1997, United States
  • DermResearchCenter of NY, Inc. /ID# 210652
    Stony Brook, New York 11790, United States
  • WDC Cosmetic and Research, PLLC /ID# 210372
    Wilmington, North Carolina 28403, United States
  • Lynn Health Science Institute (LHSI) /ID# 213216
    Oklahoma City, Oklahoma 73112, United States
  • Clinical Partners, LLC /ID# 210642
    Johnston, Rhode Island 02919, United States
  • Palmetto Clinical Trial Services /ID# 210368
    Fountain Inn, South Carolina 29644-1928, United States
  • Coastal Carolina Research Ctr /ID# 213069
    Mount Pleasant, South Carolina 29464, United States
  • Arlington Research Center, Inc /ID# 210344
    Arlington, Texas 76011, United States
  • Center for Clinical Studies - Houston (Binz) /ID# 210361
    Houston, Texas 77004-8097, United States
  • Progressive Clinical Research /ID# 210359
    San Antonio, Texas 78229, United States
  • Acclaim Dermatology /ID# 212252
    Sugar Land, Texas 77479-2645, United States
  • Dr. Samuel Sanchez, PSC /ID# 211142
    Caguas, 00727, Puerto Rico
  • Pan American Center for Oncology Trials, LLC /ID# 212445
    Rio Piedras, 00935, Puerto Rico
  • Clinical Research Puerto Rico /ID# 211144
    San Juan, 0090, Puerto Rico
09

References and documents

Publications

  • Blauvelt A, Gordon KB, Lee P, Bagel J, Sofen H, Lockshin B, Soliman AM, Geng Z, Zhan T, Alperovich G, Stein Gold L. Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. J Dermatolog Treat. 2022 Jun;33(4):2085-2093. doi: 10.1080/09546634.2021.1914812. Epub 2021 May 5. PubMed 33947295 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Feb 2020, 9 months.

Results were first posted in Mar 2021, 1 year after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 9 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2019
First posted
Mar 14, 2019
StartActual
May 13, 2019
Primary completionActual
Feb 20, 2020
CompletionActual
Jul 15, 2020
Results first posted
Mar 16, 2021
Last update
Mar 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03875482
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 14, 2019
Start date
May 13, 2019
Primary completion
Feb 20, 2020
Completion
Jul 15, 2020
Results posted
Mar 16, 2021
Last update
Mar 16, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion